Trial Profile
A retrospective study of direct acting antiviral agents for hepatitis C treatment in post kidney transplant patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ledipasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2018 New trial record
- 05 Jun 2018 Retrospective results presented at the Digestive Disease Week 2018.